Pfizer-Valneva Lyme vaccine shows 70% efficacy in large trial
TL;DR Summary
Pfizer and Valneva report that their four-dose experimental Lyme disease vaccine reduced infections by more than 70% in a 9,400-person trial and plan to seek regulatory approval, potentially becoming the first widely available Lyme vaccine; a previous vaccine, LYMErix, drew controversy despite no proven harm.
Topics:business#centers-for-disease-control-and-prevention#clinical-trials#health#lyme-disease#pfizer-inc#vaccinations
- Lyme disease vaccine shows 70 percent efficacy, Pfizer says The Washington Post
- Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal NBC News
- Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss CNBC
- Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial Yahoo Finance
- Pfizer’s Lyme vaccine results set up tricky regulatory path statnews.com
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
18 min
vs 19 min read
Condensed
99%
3,631 → 45 words
Want the full story? Read the original article
Read on The Washington Post